<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Desonide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Desonide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Desonide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11619" href="/d/html/11619.html" rel="external">see "Desonide: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="128508" href="/d/html/128508.html" rel="external">see "Desonide: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F157907"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Desonate [DSC];</li>
<li>DesOwen;</li>
<li>DesRx [DSC];</li>
<li>Tridesilon [DSC];</li>
<li>Verdeso</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866545"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>PDP-Desonide;</li>
<li>Tridesilon [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F157934"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Corticosteroid, Topical</li></ul></div>
<div class="block doa drugH1Div" id="F157910"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c67e9e2b-6dad-418d-9ecc-84f4de0f5978">Atopic dermatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis:</b> Topical: Foam, gel: Apply 2 times daily sparingly. Therapy should be discontinued when control is achieved. If no improvement is seen within 4 weeks, reassessment of diagnosis may be necessary; treatment should not exceed 4 consecutive weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fcdd7c2-fcea-459c-b474-e68d6e2cb01d">Corticosteroid-responsive dermatoses</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Corticosteroid-responsive dermatoses:</b> Topical: Cream, ointment, lotion: Apply to the affected area(s) sparingly 2 or 3 times daily (lotion) or 2 to 4 times daily (cream, ointment). Therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991133"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988465"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F157911"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F157922"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="128508" href="/d/html/128508.html" rel="external">see "Desonide: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosage should be based on severity of disease and patient response; use smallest amount for shortest period of time to avoid hypothalamic-pituitary-adrenal (HPA) axis suppression. Therapy should be discontinued when control is achieved.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c67e9e2b-6dad-418d-9ecc-84f4de0f5978">Atopic dermatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis:</b> Infants â‰¥3 months, Children, and Adolescents: Foam 0.05%, gel 0.05%: Apply a thin layer to affected area twice daily. If no improvement is seen within 4 weeks, reassessment of diagnosis may be necessary; treatment should not exceed 4 consecutive weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fcdd7c2-fcea-459c-b474-e68d6e2cb01d">Corticosteroid-responsive dermatoses</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Corticosteroid-responsive dermatoses:</b> Limited data available: Infants, Children, and Adolescents: Topical: Cream, ointment, lotion (0.05%): Apply sparingly to the affected area(s) twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7601950','lexi-content-ref-Kliegman.1','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7601950','lexi-content-ref-Kliegman.1','lexi-content-ref-NICE.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51093821"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51093822"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F157887"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased blood pressure (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (2%), irritability (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stinging of the skin (â‰¤3%), atopic dermatitis (&lt;2%; exacerbation), contact dermatitis (&lt;2%), exfoliation of skin (&lt;2%), pruritus (&lt;2%), skin irritation (&lt;2%), xeroderma (&lt;2%), skin rash (â‰¤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (2%), HPA-axis suppression (more common in pediatric patients)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal liver function (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Viral infection (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site reaction (1% to 6%), application site burning (â‰¤3%), application site atrophy (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (10%), cough (4%), asthma (1%), pharyngitis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%, postmarketing, and/or case reports: Application site erythema, application site induration, application site irritation, application-site pruritus, dermatological reaction, diaphoresis, erythema of skin, facial swelling, folliculitis, oily skin, pain, peripheral edema, pustular rash</p></div>
<div class="block coi drugH1Div" id="F157899"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to desonide or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:4em;">Verdeso: There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F157884"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.</p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Contact dermatitis: Allergic contact dermatitis can occur, it is usually diagnosed by failure to heal rather than clinical exacerbation; discontinue use if irritation occurs and treat appropriately.</p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Local effects: Local adverse reactions may occur (eg, skin atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection miliaria); may be irreversible. Local adverse reactions are more likely to occur with occlusive and/or prolonged use.</p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Ocular effects: Topical corticosteroids, including desonide, may increase the risk of posterior subcapsular cataracts and glaucoma. Monitor for ocular symptoms. Avoid contact with eyes.</p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Skin infections: Concomitant skin infections may be present or develop during therapy; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing syndrome, hyperglycemia, or glycosuria. Use of the foam for &gt;4 weeks may suppress the immune system. Absorption of topical corticosteroids is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Pediatric: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage forms specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Foam: Flammable; keep away from fire or flame. Instruct patients to avoid smoking during and immediately after application.</p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP ["Inactive" 1997]; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Appropriate use: Do not use if there is atrophy at the treatment site. Do not use with occlusive dressing.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F54484078"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Topical corticosteroids may be absorbed percutaneously. The extent of absorption is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, age of the patient, prolonged duration of use, and the use of occlusive dressings. Percutaneous absorption of topical steroids is increased in neonates (especially preterm neonates), infants, and young children. Hypothalamic-pituitary-adrenal (HPA) axis suppression may occur, particularly in younger children or in patients receiving high doses for prolonged periods; with gel or foam, application to â‰¥25% to 35% of the body for at least 4 weeks resulted in adrenal suppression in 3% to 4% of patients. Acute adrenal insufficiency (adrenal crisis) may occur with abrupt withdrawal after long-term therapy or with stress. Infants and small children may be more susceptible to HPA axis suppression or other systemic toxicities due to larger skin surface area to body mass ratio; use with caution in pediatric patients.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F157893"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">DesOwen: 0.05% (60 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tridesilon: 0.05% (60 g [DSC]) [contains cetyl alcohol, methylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (15 g, 60 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Foam, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Verdeso: 0.05% (100 g) [contains cetyl alcohol, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Desonate: 0.05% (60 g [DSC]) [contains edetate (edta) disodium dihydrate, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">DesRx: 0.05% (60 g [DSC]) [contains edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (60 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lotion, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (59 mL, 118 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (15 g, 60 g)</p></div>
<div class="block geq drugH1Div" id="F157880"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F157900"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Desonide External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $5.35</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (DesOwen External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $10.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Foam</b> (Verdeso External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $13.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Desonide External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $11.34</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Lotion</b> (Desonide External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per mL): $5.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Desonide External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $1.55 - $5.35</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866546"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tridesilon: 0.05% ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (15 g, 60 g, 454 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tridesilon: 0.05% ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (15 g, 60 g)</p></div>
<div class="block adm drugH1Div" id="F157896"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For topical use only; not for oral, ophthalmic, or intravaginal use. For use on the face, dispense desonide in hands and gently massage into affected areas of the face; for areas other than the face, desonide may be dispensed directly on the affected area. Wash hands after use (unless hands are part of the treatment area). Do not use on open wounds; apply sparingly using smallest amount needed to adequately cover the affected area. Use of occlusive dressings is not recommended; do not use in the treatment of diaper dermatitis. Avoid contact with eyes or other mucous membranes.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Foam, lotion: Shake well before use. Dispense by inverting can upside down (upright actuation will cause loss of propellant). Foam is flammable; patients should not smoke during or immediately following application.</p></div>
<div class="block admp drugH1Div" id="F52612504"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical: For topical use only; not for oral, ophthalmic, or intravaginal use. Avoid contact with eyes or other mucous membranes. Do not use on open wounds; apply sparingly using smallest amount needed to adequately cover the affected area. Use of occlusive dressings is not recommended. Wash hands after use (unless hands are part of the treatment area).</p>
<p style="text-indent:-2em;margin-left:2em;">Foam: Shake well before use. For use on the face, dispense desonide in hands and gently massage into affected areas of the face; for areas other than the face, desonide may be dispensed directly on the affected area. Foam is flammable; avoid fire, flame, and/or smoking during or immediately following application.</p>
<p style="text-indent:-2em;margin-left:2em;">Gel: Should not be routinely used on the underarm or groin areas of pediatric patients; do not use in the treatment of diaper dermatitis.</p>
<p style="text-indent:-2em;margin-left:2em;">Lotion: Shake well before use.</p></div>
<div class="block use drugH1Div" id="F157894"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis (foam and gel):</b> Treatment of mild to moderate atopic dermatitis in patients 3 months and older</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Corticosteroid-responsive dermatoses (cream, ointment, and lotion):</b> Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.</p></div>
<div class="block mst drugH1Div" id="F54707826"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Medium, high, and very high potency topical corticosteroids, when used in neonates and infants &lt;1 year of age for diaper dermatitis, are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided due to risk of adrenal suppression; systemic absorption is higher in pediatric patients than adults (strong recommendation; low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299139"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F157889"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F56222780"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Topical corticosteroids may be used for the treatment of corticosteroid-responsive dermatosis, such as atopic dermatitis, in patients planning a pregnancy (Vestergaard 2019).</p></div>
<div class="block pri drugH1Div" id="F56222781"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Systemic bioavailability of topical corticosteroids is variable (eg, integrity of skin, use of occlusion) and may be further influenced by trimester of pregnancy (Chi 2017). In general, the use of topical corticosteroids is not associated with a significant risk of adverse pregnancy outcomes. However, there may be an increased risk of low-birth-weight infants following maternal use of potent or very potent topical products, especially in high doses, although this risk is likely to be low (Andersson 2021; Chi 2015; Chi 2017).</p>
<p style="text-indent:0em;margin-top:2em;">When first-line treatments, such as emollients, are insufficient, topical corticosteroids may be used for the treatment of atopic dermatitis in pregnant patients (Vestergaard 2019). Topical corticosteroids are classified by potency; the medication and formulation (eg, cream, gel, and/or salt form) contribute to the potency classification (Oakley 2021; Stacey 2021; Tadicherla 2009). In general, use of the least potent product in limited amounts is recommended during pregnancy. Mild to moderate potency corticosteroids are preferred; potent to very potent topical corticosteroids should only be used as alternative therapy in limited amounts under obstetrical care. Pregnant patients should avoid application of topical corticosteroids to areas with high percutaneous absorption (eg, arm pit, skin folds, vulva) (Chi 2017), and caution should be used when applying to areas prone to striae formation (eg, abdomen, breast, thighs) (Vestergaard 2019).</p></div>
<div class="block brc drugH1Div" id="F3401420"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if desonide is present in breast milk following topical application; however, systemically administered corticosteroids are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Topical corticosteroids are generally considered acceptable for use in patients who are breastfeeding (Butler 2014; WHO 2002).</p>
<p style="text-indent:-2em;margin-left:2em;">Avoid application of topical corticosteroids to the nipple and areola area until breastfeeding ceases; hypertension was noted in a breastfed infant when a high-potency topical corticosteroid was applied to the nipple (AAD-NPF [Elmets 2021]; Butler 2014; Leachman 2006). If needed, apply topical corticosteroids immediately after breastfeeding, then clean nipples prior to the next feeding (Vestergaard 2019).</p></div>
<div class="block mop drugH1Div" id="F10111945"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">HPA axis suppression (ACTH stimulation test, AM plasma cortisol test, urinary free cortisol test); signs of bacterial or fungal infection; ocular symptoms</p></div>
<div class="block pha drugH1Div" id="F157883"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A<sub>2</sub> inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid.  Desonide has low range potency.</p></div>
<div class="block phk drugH1Div" id="F157898"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Dependent on formulation, amount applied and nature of skin at application site; may be increased with inflammation or occlusion </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Primarily urine; bile</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F157901"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Reticus</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Desowen | Esteronide | Locatop</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Desowen</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Desotop</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Sterax</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Locatop</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Dermatol | Desonida | Desonol | Desoskin | Desowen | Neonid | Steronide</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">CÃ´te d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Locapred | Locatop | Tridesonit</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Desowen | Sterax</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Desowen | Li yan zhuo</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dermosupril | Desinol | Desonida | Desonix | Desowen | Impo derm | Locorten desonida | Tresilen | Tridesilon</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Sterax</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Dermosupril | Desowen | Prenacid | Tridesilon | Zotinar</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dermosupril | Dorzam | Maxiderm | Tridesilon</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Prenacid</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Desofective | Despruderm | Locoprex</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Apolar</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Desonide rpg | Locapred | Locatop | Tridesonit</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Tridesilon miles | Tridesilon sandoz</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Desolex | Desowen</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Apolar | Dermades | Dermanide | Desolex | Meprolar | Nufapolar</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Locatop</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Atonide | Dermanide | Desoadd | Desoint | Desomild | Desosoft | Desowen | Disofit | Dosetil | Gracecort</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Nutragent | Pr 100 | Prenacid | Reticus | Sterades</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Dosetil</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Atomax | Carederm | Dermonide | Desoclin | Desocort | Desoderm | Desona | Desonel | Desonia | Desonium | Desowen | Deswon | Dongkoo dermo | Jeswen | Mild One | Naris | Topiderm</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Locatop</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Locapred | Locatop</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Prednol</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Locapred | Locatop | Sterax</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Prednol</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Locapred | Locatop</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Dermalive | Desowen | Prylemid</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ezenide</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Dosetil</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Apolar</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Desowen</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dermosupril | Desonida | Prenacid</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Desowen | Dosetil | Sterax</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Prenacid</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Locatop</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Desonate | Desowen | Desrx | Tridesilon</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Locapred | Zotinar | Zotinar capilar</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Dermosupril</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Prenacid</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Reticus</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Desowen</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Locapred | Locatop | Prenacid</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Prednol | Prenacid</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dermosupril | Desowen | Segucort</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dermosupril | Desowen | Erilon | Locatop | Tridesilon</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Locatop</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desonide-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33950165">
<a name="33950165"></a>Andersson NW, Skov L, Andersen JT. Evaluation of topical corticosteroid use in pregnancy and risk of newborns being small for gestational age and having low birth weight. <i>JAMA Dermatol</i>. 2021;157(7):788-795. doi:10.1001/jamadermatol.2021.1090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desonide-drug-information/abstract-text/33950165/pubmed" id="33950165" target="_blank">33950165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.e1-417.e10; quiz 427. doi:10.1016/j.jaad.2013.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desonide-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26497573">
<a name="26497573"></a>Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. <i>Cochrane Database Syst Rev</i>. 2015;(10):CD007346. doi:10.1002/14651858.CD007346.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desonide-drug-information/abstract-text/26497573/pubmed" id="26497573" target="_blank">26497573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28233354">
<a name="28233354"></a>Chi CC, Kirtschig G, Aberer W, et al. Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. <i>J Eur Acad Dermatol Venereol</i>. 2017;31(5):761-773. doi:10.1111/jdv.14101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desonide-drug-information/abstract-text/28233354/pubmed" id="28233354" target="_blank">28233354</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Desonate gel (desonide) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; July 2019.</div>
</li>
<li>
<div class="reference">
                  Desonide cream and ointment [prescribing information]. Hawthorne, NY: Taro; October 2015.</div>
</li>
<li>
<div class="reference">
                  Desonide ointment [prescribing information]. Durham, NC: Encube Ethicals Inc; June 2019.</div>
</li>
<li>
<div class="reference">
                  DesOwen (desonide cream, ointment, and lotion) [prescribing information]. Fort Worth, TX: Galderma Laboratories; May 2014.</div>
</li>
<li>
<div class="reference">
                  DesOwen (desonide cream and lotion) [prescribing information]. Fort Worth, TX: Galderma Laboratories; April 2017.</div>
</li>
<li>
<div class="reference">
                  DesRx (desonide) [prescribing information]. Wilmington, DE: Eckson Labs; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32738429">
<a name="32738429"></a>Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>J Am Acad Dermatol</i>. 2021;84(2):432-470. doi:10.1016/j.jaad.2020.07.087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desonide-drug-information/abstract-text/32738429/pubmed" id="32738429" target="_blank">32738429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12441327">
<a name="12441327"></a>Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi's sarcoma. <i>J Natl Cancer Inst</i>. 2002;94(22):1712-1718.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desonide-drug-information/abstract-text/12441327/pubmed" id="12441327" target="_blank">12441327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7601950">
<a name="7601950"></a>Jorizzo J, Levy M, Lucky A, et al. Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients. <i>J Am Acad Dermatol</i>. 1995;33(1):74-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desonide-drug-information/abstract-text/7601950/pubmed" id="7601950" target="_blank">7601950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677965">
<a name="16677965"></a>Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. <i>Dermatol Clin</i>. 2006;24(2):167-197, vi. doi:10.1016/j.det.2006.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desonide-drug-information/abstract-text/16677965/pubmed" id="16677965" target="_blank">16677965</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  LoKara (desonide lotion) [prescribing information]. Duluth, GA: Pharmaderm; 2006.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desonide-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528911">
<a name="24528911"></a>Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. <i>J Am Acad Dermatol</i>. 2014;70(3):401.e1-401.e14; quiz 415. doi:10.1016/j.jaad.2013.09.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desonide-drug-information/abstract-text/24528911/pubmed" id="24528911" target="_blank">24528911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33108015">
<a name="33108015"></a>Oakley R, Arents BWM, Lawton S, Danby S, Surber C. Topical corticosteroid vehicle composition and implications for clinical practice. <i>Clin Exp Dermatol</i>. 2021;46(2):259-269. doi:10.1111/ced.14473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desonide-drug-information/abstract-text/33108015/pubmed" id="33108015" target="_blank">33108015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>NICE. Management of atopic eczema in children from birth up to the age of 12 years. Clinical guideline. December 2007. http://www.nice.org.uk/guidance/cg57/evidence/full-guideline-196612237
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desonide-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33719380">
<a name="33719380"></a>Stacey SK, McEleney M. Topical corticosteroids: choice and application. <i>Am Fam Physician</i>. 2021;103(6):337-343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desonide-drug-information/abstract-text/33719380/pubmed" id="33719380" target="_blank">33719380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20027937">
<a name="20027937"></a>Tadicherla S, Ross K, Shenefelt PD, Fenske NA. Topical corticosteroids in dermatology. <i>J Drugs Dermatol</i>. 2009;8(12):1093-1105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desonide-drug-information/abstract-text/20027937/pubmed" id="20027937" target="_blank">20027937</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Tridesilon (desonide cream) [prescribing information]. Bronx, NY: Perrigo; February 2016.</div>
</li>
<li>
<div class="reference">
                  Verdeso (desonide foam) [prescribing information]. Exon, PA: Almirall LLC; April 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31231864">
<a name="31231864"></a>Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. <i>J Eur Acad Dermatol Venereol</i>. 2019;33(9):1644-1659. doi:10.1111/jdv.15709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desonide-drug-information/abstract-text/31231864/pubmed" id="31231864" target="_blank">31231864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. http://www.who.int/maternal_child_adolescent/documents/55732/en. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desonide-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9331 Version 351.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
